Stock comparison
IDEXX Laboratories
Ironwood Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | IRWD | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 47D | IDXX |
| Benjamin Graham | 80A | 25F | IDXX |
| Philip Fisher | 75B | 41D | IDXX |
| Peter Lynch | 71B | 26F | IDXX |
| Joel Greenblatt | 83C | 69B | IDXX |
| Charlie Munger | 87A | 68D | IDXX |
| Terry Smith | 84A | 66C | IDXX |
Side-by-side metrics
| Metric | IDXX | IRWD |
|---|---|---|
| Market cap | $44.12B | $645.28M |
| P/E (TTM) | 39.0x | 4.5x |
| EV/EBIT | 31.6x | 9.0x |
| ROIC (TTM) | 40.66% | 43.86% |
| Gross margin | 62.05% | 99.75% |
| Net margin | 24.63% | 41.76% |
| Revenue CAGR 5y | 7.56% | -8.02% |
| EPS CAGR 5y | 10.79% | -53.69% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs -8.02%+194%
- EPS CAGR 5y10.79%vs -53.69%+120%
- Market cap$44.12Bvs $645.28M+99%
IRWD leads on
- Debt / Equity-vs 0.7x+125%
- P/E (TTM)4.5xvs 39.0x+88%
- EV/EBIT9.0xvs 31.6x+72%
- Net margin41.76%vs 24.63%+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.